Exhibit 10.1


 


PURCHASE AGREEMENT


 


PURCHASE AGREEMENT
(this “Agreement”), dated as of January 7, 2021, by and among ONCONOVA THERAPEUTICS, INC.,
a Delaware corporation (the “Company”), and the investors identified on Schedule I hereto (each, an “Investor”
and collectively, the “Investors”).


 


WHEREAS:


 


Subject to the terms and conditions set
forth in this Agreement, the Company wishes to sell to the Investors, and the Investors wish to buy from the Company, the shares
listed on Schedule I hereto (the “Purchase Shares”) of the Company's common stock, $0.01 par value per
share (the “Common Stock”), at an aggregate purchase price of $8,700,250.


 


NOW THEREFORE, in consideration of the
mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the Company and the Investors hereby agree as follows:


 


1.               CERTAIN
DEFINITIONS.


 


For purposes of this
Agreement, the following terms shall have the following meanings:


 


(a)            “Bankruptcy
Law” means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.


 


(b)            “Base
Prospectus” means the Company’s final base prospectus, dated May 18, 2020, a preliminary form of which is
included in the Registration Statement, including the documents incorporated by reference therein.


 


(c)            “Business
Day” means any day on which the Principal Market is open for trading, including any day on which the Principal Market
is open for trading for a period of time less than the customary time.


 


(d)            “Confidential
Information” means any information disclosed by either party to the other party, either directly or indirectly, in writing,
orally or by inspection of tangible objects (including, without limitation, documents, prototypes, samples, plant and equipment),
which is designated as "Confidential," "Proprietary" or some similar designation. Information communicated
orally shall be considered Confidential Information if such information is confirmed in writing as being Confidential Information
within ten (10) Business Days after the initial disclosure. Confidential Information may also include information disclosed
to a disclosing party by third parties. Confidential Information shall not, however, include any information which (i) was
publicly known and made generally available in the public domain prior to the time of disclosure by the disclosing party; (ii) becomes
publicly known and made generally available after disclosure by the disclosing party to the receiving party through no action or
inaction of the receiving party; (iii) is already in the possession of the receiving party without confidential restriction
at the time of disclosure by the disclosing party as shown by the receiving party’s files and records immediately prior to
the time of disclosure; (iv) is obtained by the receiving party from a third party without a breach of such third party’s
obligations of confidentiality; (v) is independently developed by the receiving party without use of or reference to the disclosing
party’s Confidential Information, as shown by documents and other competent evidence in the receiving party’s possession;
or (vi) is required by law to be disclosed by the receiving party, provided that the receiving party gives the disclosing
party prompt written notice of such requirement prior to such disclosure and assistance in obtaining an order protecting the information
from public disclosure.


 






    


     


    

 


(e)            “Custodian”
means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.


 


(f)            “DTC”
means The Depository Trust Company, or any successor performing substantially the same function for the Company.


 


(g)            “DWAC
Shares” means shares of Common Stock that are (i) issued in electronic form, (ii) freely tradable and transferable
and without restriction on resale and (iii) timely credited by the Company to the Investor or its designee’s specified
Deposit/Withdrawal at Custodian (DWAC) account with DTC under its Fast Automated Securities Transfer (FAST) Program or any similar
program hereafter adopted by DTC performing substantially the same function.


 


(h)            “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.


 


(i)            “Initial
Prospectus Supplement” means the prospectus supplement of the Company dated January 7, 2021 relating to the Purchase
Shares, including the accompanying Base Prospectus, to be prepared and filed by the Company with the SEC pursuant to Rule 424(b)(5) under
the Securities Act and in accordance with Section 5(a) hereof, together with all documents and information incorporated
therein by reference.


 


(j)            “Material
Adverse Effect” means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the
results of operations, assets, business or financial condition of the Company and its Subsidiaries, taken as a whole, other than
any material adverse effect that resulted primarily from (A) any change in the United States or foreign economies or securities
or financial markets in general that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole,
(B) any change that generally affects the industry in which the Company and its Subsidiaries operate that does not have a
disproportionate effect on the Company and its Subsidiaries, taken as a whole, (C) any change arising in connection with earthquakes,
hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities,
acts of war, sabotage or terrorism or military actions existing as of the date hereof, (D) any action taken by the Investor,
its affiliates or its successors and assigns with respect to the transactions contemplated by this Agreement, (E) the effect
of any change in applicable laws or accounting rules that does not have a disproportionate effect on the Company and its Subsidiaries,
taken as a whole, (F) any change resulting from compliance with terms of this Agreement or the consummation of the transactions
contemplated by this Agreement, or (G) any change, in and of itself, in the Company’s stock price or trading volume
from and after the date hereof (provided, however, that the facts and circumstances underlying any
such change may, except as may be provided in subsections (A), (B), (C) (D), (E) or (F) of this definition, be considered
in determining whether a Company Material Adverse Effect has occurred), or (iii) the Company’s ability to perform
in any material respect on a timely basis its obligations under any Transaction Document to be performed as of the date of determination.


 


(k)            “Person”
means an individual or entity including but not limited to any limited liability company, a partnership, a joint venture, a corporation,
a trust, an unincorporated organization and a government or any department or agency thereof.


 


(l)            “Principal
Market” means The Nasdaq Capital Market (or any nationally recognized successor thereto); provided, however, that in
the event the Company’s Common Stock is ever listed or traded on The Nasdaq Global Market, The Nasdaq Global Select Market,
the New York Stock Exchange, the NYSE American, the NYSE Arca, the OTC Bulletin Board, or the OTCQX or the OTCQB operated by the
OTC Markets Group, Inc. (or any nationally recognized successor to any of the foregoing), then the “Principal Market”
shall mean such other market or exchange on which the Company’s Common Stock is then listed or traded.


 






    -2-


     


    

 


(m)            “Prospectus”
means the Base Prospectus, as supplemented by any Prospectus Supplement (including the Initial Prospectus Supplement), including
the documents and information incorporated by reference therein.


 


(n)            “Prospectus
Supplement” means any prospectus supplement to the Base Prospectus (including the Initial Prospectus Supplement) filed
with the SEC pursuant to Rule 424(b) under the Securities Act in connection with the transactions contemplated by this
Agreement, including the documents and information incorporated by reference therein.


 


(o)            “Registration
Statement” means the effective registration statement on Form S-3 (Commission File No. 333-237844) filed by
the Company with the SEC pursuant to the Securities Act for the registration of shares of its Common Stock, including the Purchase
Shares, and certain other securities, as such Registration Statement has been or may be amended and supplemented from time to time,
including all documents filed as part thereof or incorporated by reference therein, and including all information deemed to be
a part thereof at the time of effectiveness pursuant to Rule 430B of the Securities Act, including any comparable successor
registration statement filed by the Company with the SEC pursuant to the Securities Act for the registration of shares of its Common
Stock, including the Purchase Shares.


 


(p)            “SEC”
means the U.S. Securities and Exchange Commission.


 


(q)            “Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.


 


(r)            “Subsidiary”
means any Person the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the voting
stock or similar voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation S-K promulgated
under the Securities Act.


 


(s)            “Transaction
Documents” means, collectively, this Agreement and the schedules and exhibits hereto, and each of the other agreements,
documents, certificates and instruments entered into or furnished by the parties hereto in connection with the transactions contemplated
hereby and thereby.


 


(t)             “Transfer
Agent” means EQ Shareowner Services or such other Person who is then serving as the transfer agent for the Company in
respect of the Common Stock.


 


2.              PURCHASE OF COMMON STOCK.


 


Subject to the terms
and conditions set forth in this Agreement, the Company desires to sell to the Investor, and the Investor desires to purchase from
the Company, the Purchase Shares as follows:


 


(a)            Purchase
of Common Stock. Upon the satisfaction of the conditions set forth in Sections 7 and 8 hereof (the “Closing”
and the date of satisfaction of such conditions the “Closing Date”), the Investors shall purchase the number
of Purchase Shares set forth opposite their respective names on Schedule I hereto, at a price of $0.445 per Purchase Share.


 






    -3-


     


    

 


(b)            Payment
of Purchase Price. Each of the Investors shall pay the amount of cash for the number of Purchase Shares it is purchasing hereunder
set forth opposite its name on Schedule I hereto to the Company as full payment for all of the Purchase Shares to be purchased
by it hereunder by wire transfer of immediately available funds on the same Business Day that such Investor receives verbal or
written confirmation of delivery from the Transfer Agent of all of the Purchase Shares being purchased by such Investor as DWAC
Shares, if all of such Purchase Shares are so received by such Investor before 1:00 p.m., Eastern time, or, if any of such Purchase
Shares are received by such Investor after 1:00 p.m., Eastern time, the next Business Day. All payments made under this Agreement
shall be made in lawful money of the United States of America or wire transfer of immediately available funds to the account designated
by the Company by written notice to each of the Investors prior to the date of this Agreement.


 


(c)            Beneficial
Ownership Limitation. Notwithstanding anything to the contrary contained in this Agreement, the Company shall not issue
or sell, and none of the Investors shall purchase or acquire, any shares of Common Stock under this Agreement which, when
aggregated with all other shares of Common Stock then beneficially owned by such Investor and its respective affiliates (as calculated
pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder) would result in the beneficial
ownership by such Investor and its respective affiliates of more than 9.99% of the then issued and outstanding shares
of Common Stock (the “Beneficial Ownership Limitation”).


 


3.              INVESTORS’
REPRESENTATIONS AND WARRANTIES.


 


Each Investor, severally
and only with respect to itself and not jointly, represents and warrants to the Company that as of the date hereof and as of the
Closing Date:


 


(a)            Organization,
Authority. Such Investor is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction
of its organization, with the requisite power and authority to enter into and to consummate the transactions contemplated by this
Agreement and otherwise to carry out its obligations hereunder and thereunder.


 


(c)            Accredited
Investor Status. Such Investor is an “accredited investor” as that term is defined in Rule 501(a)(3) of
Regulation D promulgated under the Securities Act.


 


(d)            Information.
Such Investor understands that its investment in the Purchase Shares involves a high degree of risk. Such Investor (i) is
able to bear the economic risk of an investment in the Purchase Shares including a total loss thereof, (ii) has such knowledge
and experience in financial and business matters that it is capable of evaluating the merits and risks of the proposed investment
in the Purchase Shares and (iii) has had an opportunity to ask questions of and receive answers from the officers of the Company
concerning the financial condition and business of the Company and others matters related to an investment in the Purchase Shares.
Neither such inquiries nor any other due diligence investigations conducted by such Investor or its representatives shall modify,
amend or affect such Investor's right to rely on the Company's representations and warranties contained in Section 4 below.
Such Investor has sought such accounting, legal and tax advice from its own independent advisors as it has considered necessary
to make an informed investment decision with respect to its acquisition of the Purchase Shares.


 


(e)            No
Governmental Review. Such Investor understands that no U.S. federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Purchase Shares or the fairness or suitability of an investment
in the Purchase Shares nor have such authorities passed upon or endorsed the merits of the offering of the Purchase Shares.


 






    -4-


     


    

 


(f)            Validity;
Enforcement. This Agreement has been duly and validly authorized, executed and delivered on behalf of such Investor and is
a valid and binding agreement of such Investor enforceable against the Investor in accordance with its terms, subject as to enforceability
to general principles of equity and to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar
laws relating to, or affecting generally, the enforcement of applicable creditors' rights and remedies.


 


(g)            Residency.
Such Investor is a resident of the state set forth opposite such Investor’s name on Schedule I hereto.


 


(h)            No
Short Selling. Such Investor represents and warrants to the Company that (i) at no time prior to the date of this Agreement
has such Investor or any of its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly
or indirectly, any (A) "short sale" (as such term is defined in Rule 200 of Regulation SHO of the Exchange
Act) of the Common Stock or (B) hedging transaction, which establishes a net short position with respect to the Common Stock,
and (ii) neither such Investor nor any of its agents, representatives or affiliates shall engage in any of the aforementioned
transactions in clause (i) hereof at any time beginning on the date of this Agreement.


 


(i)            No
additional Shares. Except as otherwise disclosed in writing by each Investor, as applicable, to the Company, none of the Investors
beneficially own any securities of the Company prior to the date of this Agreement.


 


4.              REPRESENTATIONS
AND WARRANTIES OF THE COMPANY.


 


The Company represents
and warrants to the Investors that, except as set forth in the disclosure schedules attached hereto, which exceptions shall be
deemed to be a part of the representations and warranties made hereunder, as of the date hereof and as of the Closing Date:


 


(a)            Organization
and Qualification. The Company and each of its Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite corporate
power and authority to own and use its properties and assets and to carry on its business as currently conducted.  Neither
the Company nor any of its Subsidiaries is in violation or default of any of the provisions of its respective certificate or articles
of incorporation, bylaws or other organizational or charter documents.  Each of the Company and its Subsidiaries is duly
qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the
nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so
qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse Effect
and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or
curtail such power and authority or qualification. The Company has no Subsidiaries except as set forth on Exhibit 21.1 to
the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.


 






    -5-


     


    

 


(b)            Authorization;
Enforcement; Validity. (i) The Company has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement and each of the other Transaction Documents, and to issue the Purchase Shares in accordance with the terms
hereof and thereof, (ii) the execution and delivery of this Agreement and each of the other Transaction Documents by the Company
and the consummation by it of the transactions contemplated hereby and thereby, including without limitation, the issuance of the
Purchase Shares pursuant to this Agreement, have been duly authorized by the Company's Board of Directors and no further consent
or authorization is required by the Company, its Board of Directors or its stockholders, (iii) this Agreement has been and
each of the other Transaction Document shall be on the Closing Date, duly executed and delivered by the Company and (iv) this
Agreement constitutes, and each other Transaction Document upon its execution on behalf of the Company on the Closing Date, shall
on the Closing Date constitute, the valid and binding obligations of the Company enforceable against the Company in accordance
with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors' rights
and remedies. The Board of Directors of the Company has approved the resolutions (the “Signing Resolutions”)
substantially in the form provided to the Investor to authorize this Agreement, the other Transaction Documents and the transactions
contemplated hereby and thereby. The Signing Resolutions are valid, in full force and effect and have not been modified or supplemented
in any respect. The Company has delivered to the Investor a true and correct copy of minutes of a meeting of the Board of Directors
of the Company at which the Signing Resolutions were duly adopted by the Board of Directors or a unanimous written consent adopting
the Signing Resolutions executed by all of the members of the Board of Directors of the Company. Except as set forth in this Agreement,
no other approvals or consents of the Company’s Board of Directors, any authorized committee thereof, and/or stockholders
is necessary under applicable laws and the Company’s Certificate of incorporation and/or Bylaws to authorize the execution
and delivery of this Agreement or any of the transactions contemplated hereby, including, but not limited to, the issuance of the
Purchase Shares.


 


(c)            Capitalization.
As of the date hereof, the authorized capital stock of the Company is set forth in the Company’s Quarterly Report on Form 10-Q
for the quarter ended September 30, 2020. Except as disclosed in the SEC Documents (as defined below), (i) no shares
of the Company's capital stock are subject to preemptive rights or any other similar rights or any liens or encumbrances suffered
or permitted by the Company, (ii) there are no outstanding debt securities, (iii) there are no outstanding options, warrants,
scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible
into, any shares of capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements
by which the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company
or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries, (iv) there
are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any of
their securities under the Securities Act, (v) there are no outstanding securities or instruments of the Company or any of
its Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or
arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any
of its Subsidiaries, (vi) there are no securities or instruments containing anti-dilution or similar provisions that will
be triggered by the issuance of the Purchase Shares as described in this Agreement and (vii) the Company does not have any
stock appreciation rights or "phantom stock" plans or agreements or any similar plan or agreement. The Company has furnished
to the Investor true and correct copies of the Company's certificate of incorporation, as amended and as in effect on the date
hereof (the "Certificate of incorporation"), and the Company's Bylaws, as amended and as in effect on the date
hereof (the "Bylaws"), and summaries of the material terms of all securities convertible into or exercisable for
Common Stock, if any, and copies of any documents containing the material rights of the holders thereof in respect thereto that
are not disclosed in the SEC Documents.


 


(d)            Issuance
of Purchase Shares. Upon issuance and payment therefor in accordance with the terms and conditions of this Agreement, the Purchase
Shares shall be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens, charges, restrictions,
rights of first refusal and preemptive rights with respect to the issue thereof, and will be issued in compliance with all federal
and state securities laws, with the holders being entitled to all rights accorded to a holder of shares of Common Stock. The Purchase
Shares are being issued pursuant to the Registration Statement and the issuance of the Purchase Shares has been registered by the
Company pursuant to the Securities Act. Upon receipt of the Purchase Shares, the Investor will have good and marketable title to
such Purchase Shares and such Purchase Shares will be immediately freely tradable.


 






    -6-


     


    

 


(e)            No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the
Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Purchase Shares)
will not (i) result in a violation of the Certificate of incorporation, any Certificate of Designations, Preferences and Rights
of any outstanding series of preferred stock of the Company or the Bylaws or (ii) conflict with, or constitute a default (or
an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries
is a party, or result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities
laws and regulations and the rules and regulations of the Principal Market applicable to the Company or any of its Subsidiaries)
or by which any property or asset of the Company or any of its Subsidiaries is bound or affected, except in the case of conflicts,
defaults, terminations, amendments, accelerations, cancellations and violations under clause (ii), which could not reasonably be
expected to result in a Material Adverse Effect. Neither the Company nor its Subsidiaries is in violation of any term of or in
default under its Certificate of incorporation, any Certificate of Designation, Preferences and Rights of any outstanding series
of preferred stock of the Company or Bylaws or their organizational charter or bylaws, respectively. Neither the Company nor any
of its Subsidiaries is in violation of any term of or is in default under any material contract, agreement, mortgage, indebtedness,
indenture, instrument, judgment, decree or order or any statute, rule or regulation applicable to the Company or its Subsidiaries,
except for possible conflicts, defaults, terminations or amendments that could not reasonably be expected to have a Material Adverse
Effect. The business of the Company and its Subsidiaries is not being conducted, and shall not be conducted, in violation of any
law, ordinance or regulation of any governmental entity, except for possible violations, the sanctions for which either individually
or in the aggregate could not reasonably be expected to have a Material Adverse Effect. Except as required under the Securities
Act or applicable state securities laws and the rules and regulations of the Principal Market, the Company is not required
to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or
any regulatory or self-regulatory agency in order for it to execute, deliver or perform any of its obligations under or contemplated
by the Transaction Documents in accordance with the terms hereof or thereof. Except as set forth elsewhere in this Agreement, all
consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence
shall be obtained or effected on or prior to the Closing Date. Except as disclosed in the SEC Documents, since one year prior to
the date hereof, the Company has not received nor delivered any notices or correspondence from or to the Principal Market, other
than notices with respect to listing of additional shares of Common Stock and other routine correspondence. Except as disclosed
in the SEC Documents, the Principal Market has not commenced any delisting proceedings against the Company.


 


(f)            SEC
Documents; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,
for the twelve months preceding the date hereof (or such shorter period as the Company was required by law or regulation to file
such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being
collectively referred to herein as the “SEC Documents”) on a timely basis or has received a valid extension
of such time of filing and has filed any such SEC Documents prior to the expiration of any such extension.  As of their
respective dates and to the Company’s knowledge, the SEC Documents complied in all material respects with the requirements
of the Securities Act and the Exchange Act, as applicable. None of the SEC Documents, when filed, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company
included in the SEC Documents comply in all material respects with applicable accounting requirements and the rules and regulations
of the SEC with respect thereto as in effect at the time of filing.  Such financial statements have been prepared in
accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved
(“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto and except
that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects
the financial position of the Company as of and for the dates thereof and the results of operations and cash flows for the periods
then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. Except as set forth
in the SEC Documents, the Company has received no notices or correspondence from the SEC for the one year preceding the date hereof.
To the Company’s knowledge, the SEC has not commenced any enforcement proceedings against the Company.


 






    -7-


     


    

 


(g)            Absence
of Certain Changes. Except as disclosed in the SEC Documents, since December 31, 2019, there has been no material adverse
change in the business, properties, operations, financial condition or results of operations of the Company or its Subsidiaries.
The Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any Bankruptcy
Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate
involuntary bankruptcy or insolvency proceedings. The Company is financially solvent and is generally able to pay its debts as
they become due.


 


(h)            Absence
of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government
agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries, threatened
against or affecting the Company, the Common Stock or any of the Company's or its Subsidiaries' officers or directors in their
capacities as such, which could reasonably be expected to have a Material Adverse Effect.


 


(i)            Acknowledgment
Regarding Investors’ Status. The Company acknowledges and agrees that each of the Investors are acting solely in the
capacity of an arm's length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby.
The Company further acknowledges that none of the Investors are acting as a financial advisor or fiduciary of the Company (or in
any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby and thereby and any advice
given by any of the Investors or any of their respective representatives or agents in connection with the Transaction Documents
and the transactions contemplated hereby and thereby is merely incidental to such Investor's purchase of the Purchase Shares. The
Company further represents to each of the Investors that the Company's decision to enter into the Transaction Documents has been
based solely on the independent evaluation by the Company and its representatives and advisors.


 


(j)            No
Integrated Offering. Neither the Company, nor or any of its affiliates, nor any Person acting on their behalf has, directly
or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would
cause this offering of the Purchase Shares to be integrated with prior offerings by the Company in a manner that would require
stockholder approval pursuant to the rules of the Principal Market on which any of the securities of the Company are listed
or designated. The issuance and sale of the Purchase Shares hereunder does not contravene the rules and regulations of the
Principal Market.


 






    -8-


     


    

 


(k)            Intellectual
Property Rights. The Company and its Subsidiaries own or possess adequate rights or licenses to use all material trademarks,
trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses,
approvals, governmental authorizations, trade secrets and rights necessary to conduct their respective businesses as now conducted.
None of the Company's material trademarks, trade names, service marks, service mark registrations, service names, patents, patent
rights, copyrights, inventions, licenses, approvals, government authorizations, trade secrets or other intellectual property rights
have expired or terminated, or, by the terms and conditions thereof, could expire or terminate within two years from the date of
this Agreement. Except as disclosed in the SEC Documents, the Company and its Subsidiaries do not have any knowledge of any infringement
by the Company or its Subsidiaries of any material trademark, trade name rights, patents, patent rights, copyrights, inventions,
licenses, service names, service marks, service mark registrations, trade secret or other similar rights of others, or of any such
development of similar or identical trade secrets or technical information by others, and there is no claim, action or proceeding
being made or brought against, or to the Company's knowledge, being threatened against, the Company or its Subsidiaries regarding
trademark, trade name, patents, patent rights, invention, copyright, license, service names, service marks, service mark registrations,
trade secret or other infringement, which could reasonably be expected to have a Material Adverse Effect.


 


(l)            Environmental
Laws. The Company and its Subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local
laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or
wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received all permits, licenses or
other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are
in compliance with all terms and conditions of any such permit, license or approval, except where, in each of the three foregoing
clauses, the failure to so comply could not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect.


 


(m)          Title.
Except as set forth in the SEC Documents, the Company and its Subsidiaries have good and marketable title in fee simple to all
real property owned by them and good and marketable title in all personal property owned by them that is material to the business
of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects (“Liens”)
and, except for Liens as do not materially affect the value of such property and do not materially interfere with the use made
and proposed to be made of such property by the Company and its Subsidiaries and Liens for the payment of federal, state or other
taxes, the payment of which is neither delinquent nor subject to penalties.  Any real property and facilities held under
lease by the Company and its Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company
and its Subsidiaries are in compliance with such exceptions as are not material and do not interfere with the use made and proposed
to be made of such property and buildings by the Company and its Subsidiaries.


 


(n)            Insurance.
The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company
and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been refused any insurance coverage sought or
applied for and neither the Company nor any such Subsidiary has any reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not materially and adversely affect the condition, financial or otherwise, or the earnings,
business or operations of the Company and its Subsidiaries, taken as a whole.


 


(o)            Regulatory
Permits. The Company and its Subsidiaries possess all material certificates, authorizations and permits issued by the appropriate
federal, state or foreign regulatory authorities necessary to conduct their respective businesses, and neither the Company nor
any such Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate,
authorization or permit.


 






    -9-


     


    

 


(p)            Tax
Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and each of its Subsidiaries has made or filed all federal and state income and all other
material tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent
that the Company and each of its Subsidiaries has set aside on its books provisions reasonably adequate for the payment of all
unpaid and unreported taxes) and has paid all taxes and other governmental assessments and charges that are material in amount,
shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and has set
aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such
returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority
of any jurisdiction, and the officers of the Company know of no basis for any such claim.


 


(q)            Transactions
With Affiliates.  Except as set forth in the SEC Documents,
none of the officers or directors of the Company and, to the knowledge of the Company, none of the employees of the Company is
presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors),
including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental
of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or,
to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or
is an officer, director, trustee or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting
fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee
benefits, including stock option agreements under any stock option plan of the Company.


 


(r)            Application
of Takeover Protections. The Company and its board of directors have taken or will take prior to the Closing Date all necessary
action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any
distribution under a rights agreement) or other similar anti-takeover provision under the Certificate of Incorporation or the laws
of the state of its incorporation which is or could become applicable to any of the Investors as a result of the transactions contemplated
by this Agreement, including, without limitation, the Company's issuance of the Purchase Shares and the Investors' ownership of
the Purchase Shares.


 


(s)            Disclosure.  Except
with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents that will be timely
publicly disclosed by the Company, the Company confirms that neither it nor any other Person acting on its behalf has provided
any of the Investor’s or its agents or counsel with any information that it believes constitutes or might constitute material,
non-public information which is not otherwise disclosed in the Registration Statement or any Prospectus Supplement.   The
Company understands and confirms that each of the Investors will rely on the foregoing representation in effecting purchases and
sales of securities of the Company.  All of the disclosure furnished by or on behalf of the Company to the Investor regarding
the Company, its business and the transactions contemplated hereby, including the disclosure schedules to this Agreement, is true
and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order
to make the statements made therein, in light of the circumstances under which they were made, not misleading. The press releases
disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made and when made, not misleading.  The Company acknowledges
and agrees that none of the Investors makes or has made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in Section 3 hereof and, in that case, only with respect to such Investor and
not with respect to any other Investor.


 






    -10-


     


    





 


(t)             Foreign
Corrupt Practices.  Neither the Company, nor to the knowledge
of the Company, any agent or other Person acting on behalf of the Company, has (i) directly or indirectly, used any funds
for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity,
(ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political
parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company (or made by
any Person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material
respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.


 


(u)            Registration
Statement. The Company has prepared and filed with the SEC in accordance with the provisions of the Securities Act the Registration
Statement. The Registration Statement was declared effective by order of the SEC on May 18, 2020. The Registration Statement
is effective pursuant to the Securities Act and available for the issuance of the Purchase Shares thereunder, and the Company has
not received any written notice that the SEC has issued or intends to issue a stop order or other similar order with respect to
the Registration Statement or the Prospectus or that the SEC otherwise has (i) suspended or withdrawn the effectiveness of
the Registration Statement or (ii) issued any order preventing or suspending the use of the Prospectus or any Prospectus Supplement,
in either case, either temporarily or permanently or intends or has threatened in writing to do so. The “Plan of Distribution”
section of the Prospectus permits the issuance of the Purchase Shares under the terms of this Agreement. At the time the Registration
Statement and any amendments thereto became effective, at the date of this Agreement and at each deemed effective date thereof
pursuant to Rule 430B(f)(2) of the Securities Act, the Registration Statement and any amendments thereto complied and
will comply in all material respects with the requirements of the Securities Act and did not and will not contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein
not misleading; and the Base Prospectus and any Prospectus Supplement thereto, at the time such Base Prospectus or such Prospectus
Supplement thereto was issued and on the Closing Date, complied and will comply in all material respects with the requirements
of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading; provided
that this representation and warranty does not apply to statements in or omissions from any Prospectus Supplement made in reliance
upon and in conformity with information relating to the Investor furnished to the Company in writing by or on behalf of the Investor
expressly for use therein. The Company meets all of the requirements for the use of a registration statement on Form S-3 pursuant
to the Securities Act for the offering and sale of the Purchase Shares contemplated by this Agreement in reliance on General Instruction
I.B.1. of Form S-3, and the SEC has not notified the Company of any objection to the use of the form of the Registration Statement
pursuant to Rule 401(g)(1) of the Securities Act. The Company hereby confirms that the issuance of the Purchase Shares
to the Investor pursuant to this Agreement would not result in non-compliance with the Securities Act or any of the General Instructions
to Form S-3. The Registration Statement, as of its effective date, meets the requirements set forth in Rule 415(a)(1)(x) pursuant
to the Securities Act. At the earliest time after the filing of the Registration Statement that the Company or another offering
participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act) relating to any of the
Purchase Shares, the Company was not and is not an Ineligible Issuer (as defined in Rule 405 of the Securities Act). The Company
has not distributed any offering material in connection with the offering and sale of any of the Purchase Shares, and, until none
of the Investors hold any of the Purchase Shares, shall not distribute any offering material in connection with the offering and
sale of any of the Purchase Shares, to or by any of the Investors, in each case, other than the Registration Statement or any amendment
thereto, the Prospectus or any Prospectus Supplement required pursuant to applicable law or the Transaction Documents. The Company
has not made, and agrees that unless it obtains the prior written consent of each of the Investors it will not make, an offer relating
to the Purchase Shares that would constitute a “free writing prospectus” as defined in Rule 405 under the Securities
Act. The Company shall comply with the requirements of Rules 164 and 433 under the Securities Act applicable to any such free
writing prospectus consented to by each of the Investors, including in respect of timely filing with the SEC, legending and record
keeping.


 



    -11-


     


    




 


(v)            DTC
Eligibility. The Company, through the Transfer Agent, currently participates in the DTC Fast Automated Securities Transfer
(FAST) Program and the Common Stock can be transferred electronically to third parties via the DTC Fast Automated Securities Transfer
(FAST) Program.


 


(w)            Sarbanes-Oxley.
The Company is in compliance in all material respects with all provisions of the Sarbanes-Oxley Act of 2002, as amended, which
are applicable to it as of the date hereof.


 


(x)             Certain
Fees. No brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor
or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by
the Transaction Documents. None of the Investors shall have any obligation with respect to any fees or with respect to any claims
made by or on behalf of other Persons for fees of a type contemplated in this Section 4(x) that may be due in connection
with the transactions contemplated by the Transaction Documents.


 


(y)            Investment
Company. The Company is not required to be registered as, and immediately after receipt of payment for the Purchase Shares
will not be required to be registered as, an “investment company” within the meaning of the Investment Company Act
of 1940, as amended.


 


(z)             Listing
and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and the
Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock pursuant to the Exchange Act nor has the Company received any notification that the SEC is currently contemplating
terminating such registration. Except as disclosed in the SEC Documents, the Company has not, in the twelve (12) months preceding
the date hereof, received any notice from any Person to the effect that the Company is not in compliance with the listing or maintenance
requirements of the Principal Market. Except as disclosed in the SEC Documents, the Company is, and has no reason to believe that
it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.


 


(aa)           Accountants.
The Company’s accountants are set forth in the SEC Documents and, to the knowledge of the Company, such accountants are an
independent registered public accounting firm as required by the Securities Act. 


 


(bb)          No
Market Manipulation. The Company has not, and to its knowledge no Person acting on its behalf has, (i) taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of any of the Purchase Shares, (ii) sold, bid for, purchased, or, paid any compensation
for soliciting purchases of, any of the Purchase Shares, or (iii) paid or agreed to pay to any Person any compensation for
soliciting another to purchase any other securities of the Company.


 


(cc)           Shell
Company Status. The Company is not currently, and has never been, an issuer identified in Rule 144(i)(1) under the
Securities Act.


 


(dd)          Stock
Option Plans. Each stock option granted by the Company under the Company’s stock option plan was granted (i) in
accordance with the terms of the Company’s stock option plan and (ii) with an exercise price at least equal to the fair
market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock
option granted under the Company’s stock option plan has been backdated. The Company has not knowingly granted, and there
is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate
the grant of stock options with, the release or other public announcement of material information regarding the Company or its
Subsidiaries or their financial results or prospects.


 






    -12-


     


    

 


(ee)          Office
of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department.


 


(ff)            Money
Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money
Laundering Laws”), and no action or proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of
the Company or any Subsidiary, threatened.


 


(gg)          Labor
Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of
the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’
employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or
any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant
in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of
its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance
with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and
conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.


 


5.              COVENANTS.


 


(a)             Filing
of Current Report and Initial Prospectus Supplement. The Company agrees that it shall, prior to 9:30 a.m., New York City Time,
on January 8, 2021, file with the SEC a report on Form 8-K relating to the transactions contemplated by, and describing
the material terms and conditions of, the Transaction Documents (the “Current Report”). The Company further
agrees that it shall, within the time required under Rule 424(b) under the Securities Act, file with the SEC the Initial
Prospectus Supplement pursuant to Rule 424(b)(5) under the Securities Act, which Initial Prospectus Supplement shall
specifically relate to the Purchase Shares and shall describe the material terms and conditions of the Transaction Documents, contain
information previously omitted at the time of effectiveness of the Registration Statement in reliance on Rule 430B under the
Securities Act, and disclose all information relating to the Purchase Shares and the transactions contemplated by the Transaction
Documents required to be disclosed in the Registration Statement and the Prospectus as of the date of the Initial Prospectus Supplement,
including, without limitation, information required to be disclosed in the section captioned “Plan of Distribution”
in the Prospectus. The Company shall provide each Investor with an opportunity to review and comment upon the final pre-filing
draft versions of the Current Report and the Initial Prospectus Supplement within a reasonable time prior to their filing with
the SEC and the Company shall give reasonable consideration to all such comments. Each Investor shall use its reasonable best efforts
to comment upon the final pre-filing draft versions of the Current Report and the Initial Prospectus Supplement within a reasonable
time after such Investor receives them from the Company. Each Investor shall furnish to the Company such information regarding
itself, the Purchase Shares beneficially owned by it and the intended method of distribution thereof, including any arrangement
between such Investor and any other Person relating to the sale or distribution of the Purchase Shares, as shall be reasonably
requested by the Company in connection with the preparation and filing of the Current Report and the Initial Prospectus Supplement,
and shall otherwise cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing
of the Current Report and the Initial Prospectus Supplement with the SEC.


 






    -13-


     


    

 


(b)            Blue
Sky. The Company shall take all such action, if any, as is reasonably necessary in order to obtain an exemption for or to register
or qualify (i) the offer and sale of the Purchase Shares to the Investors under this Agreement and (ii) any subsequent
resale of all Purchase Shares by the Investor, in each case, under applicable securities or “Blue Sky” laws of the
states of the United States in such states as is reasonably requested by any of the Investors from time to time, and shall provide
evidence of any such action so taken to each of the Investors.


 


(c)             Listing/DTC.
The Company shall promptly secure the listing of all of the Purchase Shares to be issued to the Investor hereunder on the Principal
Market (subject to official notice of issuance) and upon each other national securities exchange or automated quotation system,
if any, upon which the Common Stock is then listed, and shall use commercially reasonable efforts to maintain, so long as any shares
of Common Stock shall be so listed, such listing of all such Purchase Shares. The Company shall use commercially reasonable efforts
to maintain the listing of the Common Stock on the Principal Market and shall comply in all respects with the Company’s reporting,
filing and other obligations under the bylaws or rules and regulations of the Principal Market. Neither the Company nor any
of its Subsidiaries shall take any action that would reasonably be expected to result in the delisting or suspension of the Common
Stock on the Principal Market. The Company shall pay all fees and expenses in connection with satisfying its obligations under
this Section 5(c). The Company shall take all action necessary to ensure that its Common Stock can be transferred electronically
as DWAC Shares.


 


(d)            Prohibition
of Short Sales and Hedging Transactions. At any time on or after the date hereof, neither the Investors nor any of their respective
agents, representatives or affiliates shall in any manner whatsoever enter into or effect, directly or indirectly, any (i) “short
sale” (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Common Stock or (ii) hedging
transaction, which establishes a net short position with respect to the Common Stock.


 


(e)             Reserved.


 


(f)             Non-Public
Information. Each party hereto agrees not to disclose any Confidential Information of the other party to any third party and
shall not use the Confidential Information for any purpose other than in connection with, or in furtherance of, the transactions
contemplated hereby. Each party hereto acknowledges that the Confidential Information shall remain the property of the disclosing
party and agrees that it shall take all reasonable measures to protect the secrecy of any Confidential Information disclosed by
the other party. The Company confirms that neither it nor any other Person acting on its behalf shall provide any of the Investors
or its agents or counsel with any information that constitutes or might constitute material, non-public information, unless a simultaneous
public announcement thereof is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the
foregoing covenant by the Company or any Person acting on its behalf (as determined in the reasonable good faith judgment of any
Investor), in addition to any other remedy provided herein or in the other Transaction Documents, if such Investor is holding any
Purchase Shares at the time of the disclosure of material, non-public information, such Investor shall have the right to make a
public disclosure, in the form of a press release, public advertisement or otherwise, of such material, non-public information
without the prior approval by the Company; provided such Investor shall have first provided notice to the Company that it believes
it has received information that constitutes material, non-public information, the Company shall have at least 24 hours to publicly
disclose such material, non-public information prior to any such disclosure by such Investor, the Company shall have failed to
demonstrate to such Investor in writing within such time period that such information does not constitute material, non-public
information, and the Company shall have failed to publicly disclose such material, non-public information within such time period.
None of the Investors shall have any liability to the Company, any of its Subsidiaries, or any of their respective directors, officers,
employees, stockholders or agents, for any such disclosure. The Company understands and confirms that each of the Investors shall
be relying on the foregoing covenants in effecting transactions in securities of the Company.


 






    -14-


     


    

 


(g)            Subsequent
Equity Issuances. From and after the date of this Agreement until sixty (60) days following the Closing Date (the “Restricted
Period”), without the prior written consent of the Investor identified as the “Lead Investor” on Schedule
I hereto (the “Lead Investor”) (which may be granted or withheld in its sole discretion), neither the Company
nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of
Common Stock or Common Stock Equivalents (or a combination of units thereof), other than in connection with an Exempt Issuance.
Each of the Investors shall be entitled to seek injunctive relief against the Company and its Subsidiaries to preclude any such
issuance, which remedy shall be in addition to any right to collect damages, without the necessity of showing economic loss and
without any bond or other security being required. “Common Stock Equivalents” means any securities of the Company
or its Subsidiaries which entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt,
preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable
for, or otherwise entitles the holder thereof to receive, Common Stock. “Exempt Issuance” means the issuance
of (i) Purchase Shares to the Investors pursuant to this Agreement, (ii) shares of Common Stock, Common Stock Equivalents
or other securities to any of the Investors pursuant to any other existing or future contract, agreement or arrangement between
the Company and such Investor, (iii) shares of Common Stock, Common Stock Equivalents or other securities upon the exercise,
exchange or conversion of any shares of Common Stock, Common Stock Equivalents or other securities held by any of the Investors
at any time, (iv)  the issuances of equity-based awards pursuant to an Approved Stock Plan (as defined below), and the issuances
of shares of Common Stock upon the exercise or conversion of any such equity-based awards, provided that during the Restricted
Period, the exercise or conversion price of any such equity-based award is not lowered, none of such options are amended to increase
the number of shares issuable thereunder and none of the terms or conditions of any such equity-based award are otherwise materially
changed in any manner that adversely affects any of the Investors, and (v) shares of Common Stock issued upon the conversion
or exercise of Common Stock Equivalents (other than equity-based awards issued pursuant to an Approved Stock Plan that are covered
by clause (iv) above) issued and outstanding on the date hereof, provided that the conversion, exercise or other method of
issuance (as the case may be) of any such Common Stock Equivalent is made solely pursuant to the conversion, exercise or other
method of issuance (as the case may be) provisions of such Common Stock Equivalent that were in effect on the date of this Agreement,
and during the Restricted Period the conversion, exercise or issuance price of any such Common Stock Equivalents (other than equity-based
awards issued pursuant to an Approved Stock Plan that are covered by clause (iv) above) is not lowered, none of such Common
Stock Equivalents (other than equity-based awards issued pursuant to an Approved Stock Plan that are covered by clause (iv) above)
are amended to increase the number of shares issuable thereunder and none of the terms or conditions of any such Common Stock Equivalents
(other than standard options to purchase Common Stock issued pursuant to an Approved Stock Plan that are covered by clause (iv) above)
are otherwise materially changed in any manner that adversely affects any of the Investors. “Approved Stock Plan”
means any employee benefit plan which has been approved by the board of directors of the Company prior to or subsequent to the
date hereof.


 






    -15-


     


    

 


(h)            Taxes.
The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the issuance and delivery
of any shares of Common Stock to the Investors made under this Agreement.


 


(i)              Securities
Law Compliance. For so long as any Investor holds any Purchase Shares, the Company shall (a) take all action necessary
to cause the Common Stock to continue to be registered as a class of securities under Sections 12(g) or 12(b) of the
Exchange Act, shall comply with its reporting and filing obligations under the Exchange Act, and shall not take any action or file
any document (whether or not permitted by the Exchange Act) to terminate or suspend such registration or to terminate or suspend
its reporting and filing obligations under the Exchange Act, and (b) prepare and file with the SEC, at the Company’s
expense, such amendments (including, without limitation, post-effective amendments) to the Registration Statement and such Prospectus
Supplements pursuant to Rule 424(b) under the Securities Act, in each case, as may be necessary to keep the Registration
Statement effective, and to keep the Registration Statement and the Prospectus current and available for issuances and sales of
all of the Purchase Shares by the Company to the Investor. Each Investor shall furnish to the Company such information regarding
itself, its affiliates, the Purchase Shares beneficially owned by it and the intended method of distribution thereof as shall be
reasonably requested by the Company in connection with the preparation and filing of any such amendment to the Registration Statement
or any such Prospectus Supplement, and shall otherwise cooperate with the Company as reasonably requested by the Company in connection
with the preparation and filing of any such amendment to the Registration Statement or any such Prospectus Supplement. The Company
shall comply with all applicable federal, state and foreign securities laws in connection with the offer, issuance and sale by
the Company of the Purchase Shares contemplated by the Transaction Documents. Without limiting the generality of the foregoing,
neither the Company nor any of its officers, directors or affiliates will take, directly or indirectly, any action designed or
intended to stabilize or manipulate the price of any security of the Company, or which would reasonably be expected to cause or
result in, stabilization or manipulation of the price of any security of the Company.


 


(j)              Integration.
From and after the date of this Agreement, neither the Company, nor any of its affiliates will, and the Company shall use its reasonable
best efforts to ensure that no Person acting on any of their behalf will, directly or indirectly, make any offers or sales of any
security or solicit any offers to buy any security, under circumstances that would cause this offering of the Purchase Shares to
be integrated with other offerings of securities by the Company in a manner that would require stockholder approval pursuant to
the rules and regulations of the Principal Market on which any of the securities of the Company are listed or designated,
unless stockholder approval is obtained before the closing of such subsequent transaction in accordance with the rules of
such Principal Market.


 


(k)             Use
of Proceeds. The Company will use the net proceeds from the offering of the Purchase Shares as described in the Prospectus.


 


(l)             Variable
Rate Transactions. From and after the date of this Agreement until the fifth (5th) anniversary of the Closing Date,
without the prior written consent of the Lead Investor (which may be granted or withheld in its sole discretion), the Company shall
be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of
Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. “Variable
Rate Transaction” means a transaction in which the Company (A) issues or sells any debt or equity securities that
are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock either
(1) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading
prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities,
or (2) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial
issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related
to the business of the Company or the market for the Common Stock or (B) enters into any agreement (including, without limitation,
an “equity line of credit”) with any Person, other than with the Lead Investor, whereby the Company or any Subsidiary
may sell securities at a future determined price. Notwithstanding the foregoing, beginning on the Trading Day immediately following
the last day of the Restricted Period (and in no event during the Restricted Period), the Company may sell shares of Common Stock
or Common Stock Equivalents in an “at- the-market offering” (as defined in Rule 415(a)(4) under the 1933
Act) through one or more registered broker-dealer(s). The Lead Investor shall be entitled to seek injunctive relief against the
Company and its Subsidiaries to preclude any such agreement, plan, arrangement or transaction, which remedy shall be in addition
to any right to collect damages, without the necessity of showing economic loss and without any bond or other security being required.


 






    -16-


     


    

 


(m)           Participation
Right. From and after the date of this Agreement until the first (1st) anniversary of the Closing Date, and except underwritten
public offerings as set forth in clause (x) of this Section 5(m), the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents
(or a combination of units thereof) for cash consideration (a “Subsequent Financing”), unless the Company shall
have first complied with this Section 5(m).


 


(i)           
Between 4:00 p.m. and 7:00 p.m., New York time, on the second (2nd) Business Day immediately preceding the Business
Day of a proposed or intended Subsequent Financing (each, a “Subsequent Financing Date”), the Company shall
deliver to the Lead Investor a written notice of its intention to effect a Subsequent Financing (each, a “Pre-Notice”)
(the Company shall use best efforts to ensure that the Lead Investor has received and acknowledged receipt of the Pre-Notice within
such time period), which Pre-Notice shall not contain any information (including, without limitation, material, non-public information)
other than: (x) a statement that the Company proposes or intends to effect a Subsequent Financing (without disclosing the
specific terms or conditions of the proposed Subsequent Financing or the securities to be offered and sold therein, (y) a
representation that such statement (described in clause (x) above) does not constitute material, non-public information regarding
the Company, its business or its securities and (z) a statement informing the Lead Investor that it is entitled to receive
a Subsequent Financing Notice (as defined below) containing material, non-public information with respect to such Subsequent Financing
upon its timely written request in accordance with this Section 5(m).


 


(ii)          
If the Lead Investor consents to receive material, non-public information with respect to such Subsequent Financing, the Lead Investor
shall deliver a written request therefor to the Company, not later than 9:00 a.m., New York time, on the Business Day immediately
preceding the Business Day of the proposed or intended Subsequent Financing, and upon such written request by the Lead Investor
delivered to the Company prior to such time, and only upon such written request by the Lead Investor, the Company shall promptly
thereafter, but not later than two (2) hours after such written request by the Lead Investor was properly delivered to the
Company, deliver to the Lead Investor a written notice of the proposed Subsequent Financing (a “Subsequent Financing Notice”),
which shall (A) describe in reasonable detail the proposed terms and conditions of such Subsequent Financing, including, without
limitation, the proposed terms of the securities to be offered and sold in such Subsequent Financing (the “Offered Securities”),
the total amount of proceeds intended to be raised and the Person or Persons through or with whom such Subsequent Financing is
proposed to be effected, (B) include, as an attachment thereto, a term sheet or similar document setting forth the material
terms and conditions of such Subsequent Financing, including, without limitation, the material terms of the Offered Securities,
and (C) offer to issue and sell to the Lead Investor, upon the terms and subject to the conditions of the Subsequent Financing
set forth in the Subsequent Financing Notice, 50% of the Offered Securities (the “Participation Maximum”) at
the same price per Offered Security to be paid by each other Person participating in such Subsequent Financing.


 






    -17-


     


    

 


(iii)         
In the event that the Lead Investor elects to participate in such Subsequent Financing for all or any part of the Participation
Maximum, the Lead Investor must deliver a written notice to the Company prior to the later of (i) 11:00 a.m., New York time,
on the Business Day on which such proposed or intended Subsequent Financing shall occur as set forth in the Subsequent Financing
Notice and (ii) two (2) hours after the time that the applicable Subsequent Financing Notice is received by the Lead
Investor (the “Notice Termination Time”), setting forth: (A) a statement that the Lead Investor elects
to participate in such Subsequent Financing, (B) the amount of Offered Securities, which shall not exceed the Participation
Maximum, that the Lead Investor elects to purchase in such Subsequent Financing, and (C) a representation that the Lead Investor
has sufficient funds available to purchase such Offered Securities in such Subsequent Financing on the terms and subject to the
conditions set forth in the applicable Subsequent Financing Notice received by the Lead Investor (the “Notice of Acceptance”).
If the Company does not receive a Notice of Acceptance from the Lead Investor prior to the applicable Notice Termination Time,
the Lead Investor shall be deemed to have elected not to participate in the Subsequent Financing on the terms set forth in the
applicable Subsequent Financing Notice received by the Lead Investor.


 


(iv)         
Notwithstanding the foregoing, if the Company desires to change, modify or amend any of the terms or conditions of a Subsequent
Financing, or the Offered Securities to be sold therein, set forth in a Subsequent Financing Notice delivered to the Lead Investor
hereunder, the Company shall promptly, but not later than 10:00 p.m., New York time, on the Business Day immediately preceding
the Business Day on which such Subsequent Financing is intended to occur, deliver to the Lead Investor a new written Subsequent
Financing Notice describing in reasonable detail the terms and conditions of such Subsequent Financing and Offered Securities,
as amended, and the Lead Investor will again have the right to participate in such Subsequent Financing upon the terms and conditions,
as amended, set forth in such new Subsequent Financing Notice, provided the Lead Investor delivers to the Company a Notice of Acceptance
providing the information described in the penultimate sentence of Section 5(m)(iii) above, prior to the Notice Termination
Time with respect to such new Subsequent Financing Notice, which shall be the later of (I) 11:00 a.m., New York time, on the
Business Day on which such proposed Subsequent Financing providing for such amended terms and conditions as set forth in the new
Subsequent Financing Notice delivered to the Lead Investor hereunder is intended to occur and (II) two (2) hours after
the time that such new Subsequent Financing Notice was received by the Lead Investor. If by the Notice Termination Time, the Lead
Investor has delivered to the Company a Notice of Acceptance in which it has elected to purchase in such Subsequent Financing an
aggregate amount of Offered Securities that is greater than the Participation Maximum, the Lead Investor shall be deemed to have
elected to participate for the applicable Participation Maximum in the Subsequent Financing on the terms set forth in the applicable
Subsequent Financing Notice received by the Lead Investor.


 






    -18-


     


    

 


(v)          
If by the Notice Termination Time, the Lead Investor has elected to purchase in such Subsequent Financing an aggregate amount of
Offered Securities that is equal to or less than the Participation Maximum, as reflected in an Acceptance Notice delivered by the
Lead Investor to the Company prior to the Termination Time, or the Lead Investor has not elected to participate in such Subsequent
Financing, then the Company may (A) offer, issue and sell all or any part of such Offered Securities as to which a Notice
of Acceptance has not been given by the Lead Investor, including any Offered Securities the Lead Investor did not elect to purchase
pursuant to a Notice of Acceptance as part of the Participation Maximum (all such Offered Securities that are not designated in
a Notice of Acceptance as Offered Securities to be purchased by the Lead Investor in such Subsequent Financing, the “Other
Securities”), pursuant to a definitive agreement(s) (the “Subsequent Financing Agreement”), but
only to the offerees described in the Subsequent Financing Notice and only upon terms and conditions (including, without limitation,
unit prices and interest rates) that are not more favorable to the acquiring Person or Persons or less favorable to the Company
than those set forth in the most recent Subsequent Financing Notice received by the Lead Investor and (B) to publicly announce
(x) the execution of such Subsequent Financing Agreement, and (y) either (I) the consummation of the transactions
contemplated by such Subsequent Financing Agreement or (II) the termination of such Subsequent Financing Agreement, which
shall be filed with the SEC on a Current Report on Form 8-K with such Subsequent Financing Agreement and any documents contemplated
therein filed as exhibits thereto. If a definitive agreement containing the terms and conditions of such Subsequent Financing as
set forth in the Subsequent Financing Notice delivered to the Lead Investor is not entered into by the Company for any reason within
five (5) Business Days after the date the initial Subsequent Financing Notice for such Subsequent Financing was first delivered
to the Lead Investor hereunder, and to the extent that the Company determines to proceed with such Subsequent Financing, the Company
shall promptly, but not later than 10:00 p.m., New York time, on the Business Day immediately preceding the Business Day on which
such Subsequent Financing is intended to occur, deliver to the Lead Investor a new written Subsequent Financing Notice describing
in reasonable detail the terms and conditions of such Subsequent Financing and Offered Securities, as amended, and the Lead Investor
will again have the right to participate in such Subsequent Financing upon the terms and conditions, as amended, set forth in such
new Subsequent Financing Notice, provided the Lead Investor delivers to the Company a Notice of Acceptance providing the information
described in the penultimate sentence of Section 5(m)(iii) above, prior to the Notice Termination Time with respect to
such new Subsequent Financing Notice, which shall be the time period described in Section 5(m)(iv) above.


 


(vi)         
In the event the Company shall propose to sell less than all the Other Securities (any such sale to be in the manner and on the
terms specified in Section 5(m)(v) above), then the Lead Investor may, at its sole option and in its sole discretion,
reduce the number or amount of the Offered Securities specified in its Notice of Acceptance to an amount that shall be not less
than the number or amount of the Offered Securities that the Lead Investor elected to purchase pursuant to Section 5(m)(iii) above
multiplied by a fraction, (A) the numerator of which shall be the number or amount of Offered Securities the Company actually
proposes to issue, sell or exchange (including Offered Securities to be issued or sold to the Lead Investor pursuant to this Section 5(m) prior
to such reduction) and (B) the denominator of which shall be the original amount of the Offered Securities. In the event that
the Lead Investor so elects to reduce the number or amount of Offered Securities specified in its Notice of Acceptance, the Company
may not issue, sell or exchange more than the reduced number or amount of the Offered Securities unless and until such securities
have again been offered to the Lead Investor in accordance with Section 5(m)(i) and (ii) above.


 


(vii)        
Upon the closing of the issuance, sale or exchange of all or less than all of the Other Securities, the Lead Investor shall acquire
from the Company, and the Company shall issue to the Lead Investor, the number or amount of Offered Securities specified in its
Notice of Acceptance, as reduced pursuant to Section 5(m)(vi) above if the Lead Investor has so elected, upon the terms
and conditions specified in the Subsequent Financing Agreement. The purchase by the Lead Investor of any Offered Securities is
subject in all cases to the preparation, execution and delivery by the Company and the Lead Investor of a separate purchase agreement
relating to such Offered Securities reasonably satisfactory in form and substance to the Lead Investor and its counsel. Any Offered
Securities not acquired by the Lead Investor or other Persons in accordance with this Section 5(m) may not be issued,
sold or exchanged until they are again offered to the Lead Investor under the procedures specified in this Section 5(m).


 






    -19-


     


    

 


(viii)      
The Company and the Lead Investor agree that if the Lead Investor elects to participate in the Subsequent Financing, without the
prior written consent of the Lead Investor (which may be granted or withheld in its sole discretion), neither the Subsequent Financing
Agreement with respect to such Subsequent Financing nor any other transaction documents related thereto (collectively, the “Subsequent
Financing Documents”) shall include any term or provision whereby the Lead Investor shall be required to agree to any
restrictions on trading as to any securities of the Company or be required to consent to any amendment to or termination of, or
grant any waiver, release or the like under or in connection with, any agreement previously entered into with the Company or any
instrument received from the Company.


 





(ix)         
Notwithstanding anything to the contrary in this Section 5(m) and unless otherwise agreed to by the Lead Investor, the
Company shall either confirm in writing to the Lead Investor that the transaction with respect to the Subsequent Financing has
been abandoned or shall publicly disclose its intention to issue the Offered Securities, in either case, in such a manner such
that the Lead Investor will not be in possession of any material, non-public information, by the fifth (5th) Business
Day following delivery of the Subsequent Financing Notice. If by such fifth (5th) Business Day, no public disclosure
regarding a transaction with respect to the Offered Securities has been made, and no notice regarding the abandonment of such transaction
has been received by the Lead Investor, such transaction shall be deemed to have been abandoned and the Lead Investor shall not
be in possession of any material, non-public information with respect to the Company or any of its Subsidiaries. Should the Company
decide to pursue such transaction with respect to the Offered Securities, the Company shall provide the Lead Investor with another
Subsequent Financing Notice and the Lead Investor will again have the right of participation set forth in this Section 5(m).


 


(x)          
The restrictions contained in this Section 5(m) shall not apply in connection with the issuance of any Common Stock or
Common Stock Equivalents (or a combination of units thereof) in a firm commitment underwritten public offering of Common Stock
or Common Stock Equivalents (or a combination of units thereof).


 


(n)            Other
Transactions. The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement
or transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right
of the Company to perform its obligations under any of the Transaction Documents to which it is a party, including, without limitation,
the obligation of the Company to deliver the Purchase Shares to the Investors in accordance with the terms of this Agreement.


 


(o)            Investor
Lock-Up and Voting Agreement. Each Investor, severally and not jointly, hereby agrees that such Investor shall not, during
the period commencing on the date hereof and ending on the earlier of (i) the calendar day immediately following the date
established by the Company’s board of directors as the record date for the Company’s special meeting of stockholders
to be held on March 4, 2021 (the “Record Date”) and (ii) January 21, 2021 (the “Lock-Up
Period”), offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly,
any of the Purchase Shares set forth opposite such Investor’s name on Schedule I hereto that are being purchased by
such Investor hereunder. Each Investor, severally and not jointly, hereby agrees that such Investor and its affiliates shall vote
all of their shares of Common Stock, including all of the Purchase Shares being purchased by such Investor hereunder, beneficially
owned by such Investor and its affiliates on the Record Date and entitled to vote at the special meeting to be held on March 4,
2021 in favor of each Company proposal that is submitted by the Company to its stockholders for a vote at the special meeting.


 






    -20-


     


    

 



 


6.             TRANSFER
AGENT INSTRUCTIONS.


 


On the Closing Date,
the Company shall issue to the Transfer Agent (and any subsequent transfer agent) irrevocable instructions, in the form heretofore
furnished to the Company, to issue the Purchase Shares in accordance with the terms of this Agreement (the “Irrevocable
Transfer Agent Instructions”). All Purchase Shares to be issued to or for the benefit of the Investors pursuant to this
Agreement shall be issued as DWAC Shares. The Company represents and warrants to each of the Investors that no instruction other
than the Irrevocable Transfer Agent Instructions referred to in this Section 6 will be given by the Company to the Transfer
Agent with respect to the Purchase Shares, and the Purchase Shares shall otherwise be freely transferable on the books and records
of the Company. Certificates and any other instruments evidencing the Purchase Shares shall not bear any restrictive or other legend.
If any Investor effects a sale, assignment or transfer of the Purchase Shares, the Company shall permit the transfer and shall
promptly instruct the Transfer Agent (and any subsequent transfer agent) to issue DWAC Shares in such name and in such denominations
as specified by such Investor to effect such sale, transfer or assignment. The Company acknowledges that a breach by it of its
obligations hereunder will cause irreparable harm to the Investors. Accordingly, the Company acknowledges that the remedy at law
for a breach of its obligations under this Section 6 will be inadequate and agrees, in the event of a breach or threatened
breach by the Company of the provisions of this Section 6, that each of the Investors shall be entitled, in addition to all
other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without
the necessity of showing economic loss and without any bond or other security being required. The Company shall take all actions
to carry out the intent and accomplish the purposes of this Section 6, including, without limitation, delivering or causing
to be delivered all such legal opinions, consents, certificates, resolutions and instructions to the Transfer Agent (and any subsequent
transfer agent) to the extent required or requested by the Transfer Agent (or any subsequent transfer agent) or as necessary or
desirable to carry out the intent and accomplish the purposes of this Section 6. Any fees (with respect to the Transfer Agent,
counsel to the Company or otherwise) associated with the issuance of such legal opinions, consents, certificates, resolutions and
instructions shall be borne by the Company.


 


7.             CONDITIONS TO
THE COMPANY’S OBLIGATION TO ISSUE AND SELL THE PURCHASE SHARES.




 


The obligation of the
Company hereunder to issue and sell the Purchase Shares to the Investors on the Closing Date is subject to the satisfaction or,
where legally permissible, the waiver of each of the following conditions:


 


(a)           Each
of the Investors shall have executed this Agreement and delivered the same to the Company;


 


(b)           No
stop order with respect to the Registration Statement shall be pending or threatened by the SEC; and


 


(c)           The
representations and warranties of the Investors shall be true and correct in all material respects as of the date hereof and as
of the Closing Date as though made at that time.


 






    -21-


     


    

 


		8.	CONDITIONS TO THE INVESTORS’ SEVERAL AND NOT
JOINT OBLIGATION TO PURCHASE THE PURCHASE SHARES.





 


The several and not
joint obligation of each Investor under this Agreement to purchase the number of Purchase Shares set forth opposite its name on
Schedule I hereto is subject to the satisfaction or, where legally permissible, the waiver of each of the following conditions:


 


(a)           The
Company shall have executed each of the Transaction Documents to which it is a party and delivered the same to each of the Investors;


 


(b)           The
Common Stock shall be listed or quoted on the Principal Market, trading in the Common Stock shall not have been within the last
365 days suspended by the SEC or the Principal Market, and all Purchase Shares to be issued by the Company to the Investors pursuant
to this Agreement shall have been, if applicable, approved for listing or quotation on the Principal Market in accordance with
the applicable rules and regulations of the Principal Market, subject only to official notice of issuance;


 


(c)           Each
of the Investors shall have received the opinions of the Company's legal counsel dated as of the Closing Date in the form reasonably
acceptable to the Lead Investor;


 


(d)           The
representations and warranties of the Company shall be true and correct in all material respects (except to the extent that any
of such representations and warranties is already qualified as to materiality in Section 4 above, in which case, the portion
of such representations and warranties so qualified shall be true and correct without further qualification) as of the date hereof
and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date,
which shall be true and correct as of such date) and the Company shall have performed, satisfied and complied in all material respects
with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with
by the Company at or prior to the Closing Date. The Investors shall have received a certificate, executed by the CEO, President
or CFO of the Company, dated as of the Closing Date, to the foregoing effect in the form attached hereto as Exhibit A;


 


(e)           The
Board of Directors of the Company shall have adopted resolutions in substantially the form previously provided to the Investors,
which shall be in full force and effect without any amendment or supplement thereto as of the Closing Date;


 


(f)            The
Irrevocable Transfer Agent Instructions shall have been delivered to and acknowledged in writing by the Company and the Company's
Transfer Agent;


 


(g)           The
Company shall have delivered to the Investors a certificate evidencing the incorporation and good standing of the Company in the
State of Delaware issued by the Secretary of State of the State of Delaware as of a date within ten (10) Business Days of
the Closing Date;


 


(h)           The
Company shall have delivered to the Investors a certified copy of the Certificate of incorporation as certified by the Secretary
of State of the State of Delaware within ten (10) Business Days of the Closing Date;


 


(i)            The
Company shall have delivered to the Investors a secretary's certificate executed by the Secretary of the Company, dated as of the
Closing Date, in the form attached hereto as Exhibit B;


 


(j)            The
Registration Statement shall be effective and no stop order with respect to the Registration Statement shall be pending or threatened
by the SEC. The Company shall have a maximum dollar amount certain of securities, including the Purchase Shares, registered under
the Registration Statement which is sufficient to issue to the Investors not less than all of the Purchase Shares to be purchased
under the Purchase Agreement. The Current Report and the Initial Prospectus Supplement each shall have been filed with the SEC,
as required pursuant to Section 5(a), and copies of the Prospectus shall have been delivered to the Investors in accordance
with Section 5(l) hereof. The Prospectus shall be current and available for the issuance and sale of all of the Purchase
Shares by the Company to the Investors. Any other Prospectus Supplements required to have been filed by the Company with the SEC
under the Securities Act at or prior to the Closing Date shall have been filed with the SEC within the applicable time periods
prescribed for such filings under the Securities Act. All reports, schedules, registrations, forms, statements, information and
other documents required to have been filed by the Company with the SEC at or during the 12-month period immediately preceding
the Closing Date pursuant to the reporting requirements of the Exchange Act shall have been filed with the SEC within the applicable
time periods prescribed for such filings under the Exchange Act, including any applicable extension periods contemplated by the
Exchange Act;


 






    -22-


     


    

 


(k)           The
Company shall be eligible to transfer its Common Stock, including all of the Purchase Shares, electronically as DWAC Shares;


 


(l)            All
federal, state and local governmental laws, rules and regulations applicable to the transactions contemplated by the Transaction
Documents and necessary for the execution, delivery and performance of the Transaction Documents and the consummation of the transactions
contemplated thereby in accordance with the terms thereof shall have been complied with, and all consents, authorizations and orders
of, and all filings and registrations with, all federal, state and local courts or governmental agencies and all federal, state
and local regulatory or self-regulatory agencies necessary for the execution, delivery and performance of the Transaction Documents
and the consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been obtained or
made, including, without limitation, in each case those required under the Securities Act, the Exchange Act, applicable state securities
or “Blue Sky” laws or applicable rules and regulations of the Principal Market, or otherwise required by the SEC,
the Principal Market or any state securities regulators;


 


(m)          No
statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed
by any federal, state, local or foreign court or governmental authority of competent jurisdiction which prohibits the consummation
of or which would materially modify or delay any of the transactions contemplated by the Transaction Documents;


 


(n)           No
action, suit or proceeding before any federal, state, local or foreign arbitrator or any court or governmental authority of competent
jurisdiction shall have been commenced or threatened, and no inquiry or investigation by any federal, state, local or foreign governmental
authority of competent jurisdiction shall have been commenced or threatened, against the Company, or any of the officers, directors
or affiliates of the Company, seeking to restrain, prevent or change the transactions contemplated by the Transaction Documents,
or seeking material damages in connection with such transactions;


 


(o)           No
Person shall have commenced a proceeding against the Company pursuant to or within the meaning of any Bankruptcy Law;


 


(p)           The
Company, pursuant to or within the meaning of any Bankruptcy Law, shall not have (i) commenced a voluntary case, (ii) consented
to the entry of an order for relief against it in an involuntary case, (iii) consented to the appointment of a Custodian of
it or for all or substantially all of its property, or (iv) made a general assignment for the benefit of its creditors or
is generally unable to pay its debts as the same become due; and


 


(q)           A
court of competent jurisdiction shall not have entered an order or decree under any Bankruptcy Law that (i) is for relief
against the Company in an involuntary case, (ii) appoints a Custodian of the Company or for all or substantially all of its
property, or (iii) orders the liquidation of the Company or any Subsidiary.


 






    -23-


     


    

 


9.             INDEMNIFICATION.




 


In consideration of
the Investors’ execution and delivery of this Agreement and acquiring the Purchase Shares, and in addition to all of the
Company's other obligations under the Transaction Documents to which it is a party, the Company shall defend, protect, indemnify
and hold harmless each Investor and all of its affiliates, stockholders, officers, directors and employees and any of the foregoing
Person's agents or other representatives (including, without limitation, those retained in connection with the transactions contemplated
by the Transaction Documents) (collectively, the “Indemnitees”) from and against any and all actions, causes
of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective
of whether any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable
attorneys' fees and disbursements (the “Indemnified Liabilities”), incurred by any Indemnitee as a result of,
or arising out of, or relating to: (a) any misrepresentation or breach of any representation or warranty made by the Company
in any of the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, (b) any
breach of any covenant, agreement or obligation of the Company contained in any of the Transaction Documents or any other certificate,
instrument or document contemplated hereby or thereby, (c) any cause of action, suit or claim brought or made against such
Indemnitee and arising out of or resulting from the execution, delivery, performance or enforcement of any of the Transaction Documents
or any other certificate, instrument or document contemplated hereby or thereby, (d) any violation of the Securities Act,
the Exchange Act, state securities or “Blue Sky” laws, or the rules and regulations of the Principal Market in
connection with the transactions contemplated by the Transaction Documents by the Company or any of its affiliates, officers, directors
or employees, (e) any untrue statement or alleged untrue statement of a material fact contained, or incorporated by reference,
in the Registration Statement or any amendment thereto or any omission or alleged omission to state therein, or in any document
incorporated by reference therein, a material fact required to be stated therein or necessary to make the statements therein not
misleading, or (f) any untrue statement or alleged untrue statement of a material fact contained, or incorporated by reference,
in the Prospectus, or any omission or alleged omission to state therein, or in any document incorporated by reference therein,
a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading; provided, however, that (I) the indemnity contained in clause (c) of this Section 9
shall not apply to any Indemnified Liabilities which directly and primarily result from the fraud, gross negligence or willful
misconduct of an Indemnitee, (II) the indemnity contained in clauses (d), (e) and (f) of this Section 9 shall
not apply to any Indemnified Liabilities of an Investor to the extent, but only to the extent, arising out of or based upon any
untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written
information furnished to the Company by or on behalf of such Investor expressly for use in any Prospectus Supplement (it being
hereby acknowledged and agreed that the written information set forth on Exhibit C attached hereto with respect
to the Lead Investor is the only written information furnished to the Company by or on behalf of the Lead Investor expressly for
use in the Initial Prospectus Supplement), if the Prospectus was timely made available by the Company to such Investor pursuant
to Section 5(l), (III) the indemnity contained in clauses (d), (e) and (f) of this Section 9 shall not
inure to the benefit of an Investor to the extent such Indemnified Liabilities are based on a failure of such Investor to deliver
or to cause to be delivered the Prospectus made available by the Company, if such Prospectus was timely made available by the Company
pursuant to Section 5(l), and if delivery of the Prospectus by such Investor was required under the Securities Act with respect
to the Purchase Shares and such delivery by such Investor would have cured the defect giving rise to such Indemnified Liabilities,
and (IV) the indemnity in this Section 9 shall not apply to amounts paid in settlement of any claim if such settlement
is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or
delayed. To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make
the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable
law. Any required indemnification payment for any particular claim shall be made within thirty (30) days from the date an Investor
makes a written request for it. A certificate containing reasonable detail as to the amount of such indemnification submitted to
the Company by an Investor shall be conclusive evidence, absent manifest error, of the amount due from the Company to such Investor.
If any action shall be brought against any Indemnitee in respect of which indemnity may be sought pursuant to this Agreement, such
Indemnitee shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with
counsel of its own choosing reasonably acceptable to the Indemnitee. Any Indemnitee shall have the right to employ separate counsel
in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of
such Indemnitee, except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing,
(ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in
such action there is, in the reasonable opinion of such separate counsel, a material conflict on any material issue between the
position of the Company and the position of such Indemnitee, in which case the Company shall be responsible for the reasonable
fees and expenses of no more than one such separate counsel.


 






    -24-


     


    

 


10.          RESERVED.


 


11.          TERMINATION


 


This Agreement may
be terminated only as follows:


 


(a)           If
pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding
against the Company, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company makes
a general assignment for the benefit of its creditors, this Agreement shall automatically terminate without any liability or payment
to the Company (except as set forth below) without further action or notice by any Person.


 


(b)           In
the event that the Closing shall not have occurred on or before January 15, 2021, due to the failure to satisfy the conditions
set forth in Sections 7 and 8 above with respect to the Closing, either the Company, on the one hand, or any Investor, on the other
hand, shall have the option to terminate this Agreement at the close of business on such date or thereafter without liability of
any party to any other party (except as set forth below); provided, however, that the right to terminate this Agreement under this
Section 11(b) shall not be available to any party if such party is then in breach of any covenant or agreement contained
in this Agreement or any representation or warranty of such party contained in this Agreement fails to be true and correct such
that the conditions set forth in Section 7(c) or Section 8(d), as applicable, could not then be satisfied. Any termination
of this Agreement pursuant to this Section 11(b) shall be effected by written notice from the Company to each of the
Investors, or any Investor to the Company and each of the other Investors, as the case may be, setting forth the basis for the
termination hereof.


 


The representations and warranties and
covenants of the Company and the Investors contained in Sections 3, 4, 5, and 6 hereof, the indemnification provisions set forth
in Section 9 hereof and the agreements and covenants set forth in Sections 10, 11 and 12, shall survive the Closing and any
termination of this Agreement. No termination of this Agreement shall be deemed to release the Company or any Investor from any
liability for intentional misrepresentation or willful breach by such party of any of the Transaction Documents to which it is
a party.


 






    -25-


     


    

 


12.          MISCELLANEOUS.


 


(a)           Governing
Law; Jurisdiction; Jury Trial. The corporate laws of the State of Delaware shall govern all issues concerning the relative
rights of the Company and its stockholders. All other questions concerning the construction, validity, enforcement and interpretation
of this Agreement and the other Transaction Documents shall be governed by the internal laws of the State of Illinois, without
giving effect to any choice of law or conflict of law provision or rule (whether of the State of Illinois or any other jurisdictions)
that would cause the application of the laws of any jurisdictions other than the State of Illinois. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in the State of Illinois, County of Cook, for the
adjudication of any dispute hereunder or under the other Transaction Documents or in connection herewith or therewith, or with
any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action
or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding
is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably
waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy
thereof to such party at the address for such notices to it under this Agreement and the other Transaction Documents and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY
RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY OF THE OTHER TRANSACTION DOCUMENTS OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.


 


(b)           Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile
signature or signature delivered by e-mail in a “.pdf” format data file, including any electronic signature complying
with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due execution
and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.


 


(c)           Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this
Agreement.


 


(d)           Severability.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.


 


(e)           Entire
Agreement; Amendment. This Agreement and the other Transaction Documents supersede all other prior oral or written agreements
among the Investors, the Company, their respective affiliates and Persons acting on their behalf with respect to the subject matter
hereof, and this Agreement, the other Transaction Documents and the instruments referenced herein contain the entire understanding
of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein,
neither the Company nor any of the Investors makes any representation, warranty, covenant or undertaking with respect to such matters.
The Company acknowledges and agrees that is has not relied on, in any manner whatsoever, any representations or statements, written
or oral, other than as expressly set forth in the Transaction Documents. No provision of this Agreement or the other Transaction
Documents may be amended other than by a written instrument signed by each of the parties hereto or thereto.


 


(f)            Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to have been delivered: (i) upon receipt when delivered personally; (ii) upon receipt
when sent by facsimile or email (provided confirmation of transmission is mechanically or electronically generated and kept on
file by the sending party); or (iii) one Business Day after deposit with a nationally recognized overnight delivery service,
in each case properly addressed to the party to receive the same. The addresses for such communications shall be:


 






    -26-


     


    

 


 


If to the Company:


 


	Onconova Therapeutics, Inc.	 	 
	375 Pheasant Run	 	 
	Newtown, PA 18940	 	 






	Telephone:	(267)759-3680	 
	Facsimile:	(267)759-3681	 
	E-mail:	mguerin@onconova.us Attention:	Mark Guerin, Chief Financial Officer




 


With a copy to (which shall not
constitute notice or service of process):


 


	Morgan, Lewis & Bockius LLP	 
	1701 Market Street	 
	Philadelphia, PA	 






	Telephone:	(215)963-5000
	Facsimile:	(215)963-5001
	E-mail:	joanne.soslow@morganlewis.com
	Attention:	Joanne R. Soslow,Esq.




 


If to an Investor, to its address
set forth opposite its name on Schedule I hereto, with copies to such Investor’s representatives as set forth on Schedule
I hereto,


 


With a copy for informational
purposes only to (which shall not constitute notice or service of process):


 


Dorsey &
Whitney LLP


51 West
52nd Street 


New York,
NY 10019 


	Telephone:	(212)415-9214
	Facsimile:	(212)953-7201
	E-mail:	marsico.anthony@dorsey.com
	Attention:	Anthony J. Marsico,Esq.




 


If to the Transfer Agent:


 


EQ Shareowner
Services 


P.O. Box
64945 


St. Paul,
MN 55164-0874 


	Telephone:	(800)401-1957
	Attention:	Angela Stewart




 


or at such other address and/or facsimile
number and/or to the attention of such other Person as the recipient party has specified by written notice given to each other
party three (3) Business Days prior to the effectiveness of such change. Written confirmation of receipt (A) given by
the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated by the
sender's facsimile machine or email account containing the time, date, and recipient facsimile number or email address, as applicable,
and an image of the first page of such transmission or (C) provided by a nationally recognized overnight delivery service,
shall be rebuttable evidence of personal service, receipt by facsimile or email or receipt from a nationally recognized overnight
delivery service in accordance with clause (i), (ii) or (iii) above, respectively.


 






    -27-


     


    

 


(g)           Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and any permitted successors and
assigns of the Company. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written
consent of each of the Investors, including by merger or consolidation. None of the Investors may assign its rights or obligations
under this Agreement.


 


(h)           No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and any permitted successors and
assigns of the Company and, except as set forth in Section 9, is not for the benefit of, nor may any provision hereof be
enforced by, any other Person.


 


(i)            Publicity.
The Company shall afford each of the Investors and its counsel with the opportunity to review and comment upon the form and substance
of, and shall give reasonable consideration to all such comments from such Investor or its counsel on, any press release, SEC filing
or any other public disclosure by or on behalf of the Company relating to such Investor, its purchases hereunder or any aspect
of the Purchase Shares, any of the Transaction Documents or the transactions contemplated thereby, not less than 24 hours prior
to the issuance, filing or public disclosure thereof. Each Investor must be provided with a final version of any such press release,
SEC filing or other public disclosure at least 24 hours prior to any release, filing or use by the Company thereof. The Company
agrees and acknowledges that its failure to fully comply with this provision constitutes a Material Adverse Effect. Except as contemplated
in Section 5(f) hereof, no Investor shall issue a press release or any other public disclosure regarding this Agreement
or the substance hereof without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned
or delayed.


 


(j)            Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.


 


(k)            No
Financial Advisor, Placement Agent, Broker or Finder. The Company represents and warrants to each of the Investors that it
has not engaged any financial advisor, placement agent, broker or finder in connection with the transactions contemplated hereby.
Each Investor, severally and only with respect to itself and not jointly, represents and warrants to the Company that it has not
engaged any financial advisor, placement agent, broker or finder in connection with the transactions contemplated hereby. The Company
shall be responsible for the payment of any fees or commissions, if any, of any financial advisor, placement agent, broker or finder
relating to or arising out of the transactions contemplated hereby. The Company shall pay, and hold each of the Investors harmless
against, any liability, loss or expense (including, without limitation, attorneys' fees and out of pocket expenses) arising in
connection with any such claim.


 


(l)             No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.


 


(m)          Remedies,
Other Obligations, Breaches and Injunctive Relief. The Investors’ remedies provided in this Agreement, including, without
limitation, the Investors’ remedies provided in Section 9, shall be cumulative and in addition to all other remedies
available to the Investors under this Agreement, at law or in equity (including a decree of specific performance and/or other injunctive
relief), no remedy of any of the Investors contained herein shall be deemed a waiver of compliance with the provisions giving rise
to such remedy and nothing herein shall limit any Investor's right to pursue actual damages for any failure by the Company to comply
with the terms of this Agreement. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable
harm to the Investors and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the
event of any such breach or threatened breach, any Investor shall be entitled, in addition to all other available remedies, to
an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being
required.


 






    -28-


     


    

 


 


(n)           Enforcement
Costs. If: (i) this Agreement is placed by any Investor in the hands of an attorney for enforcement or is enforced by
any Investor through any legal proceeding; (ii) an attorney is retained to represent any Investor in any bankruptcy, reorganization,
receivership or other proceedings affecting creditors' rights and involving a claim under this Agreement; or (iii) an attorney
is retained to represent any Investor in any other proceedings whatsoever in connection with this Agreement, then the Company shall
pay to such Investor, as incurred by such Investor, all reasonable costs and expenses including attorneys' fees incurred in connection
therewith, in addition to all other amounts due hereunder. If this Agreement is placed by the Company in the hands of an attorney
for enforcement against an Investor or is enforced by the Company against an Investor through any legal proceeding, then such Investor
against whom this Agreement is so enforced shall pay to the Company, as incurred by the Company, all reasonable costs and expenses
including reasonable attorneys’ fees incurred in connection therewith, in addition to all other amounts due hereunder.


 


(o)           Waivers.
No provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement of
such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof
or of any other right, power or privilege.


 


(p)           Independent
Nature of Investors’ Obligations and Rights. The obligations of each Investor under the Transaction Documents are several
and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of
the obligations of any other Investor under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Investor pursuant hereto or thereto, shall be deemed to constitute the Investors as, and the Company
acknowledges that the Investors do not so constitute, a partnership, an association, a joint venture or any other kind of group
or entity, or create a presumption that the Investors are in any way acting in concert or as a group or entity with respect to
such obligations or the transactions contemplated by the Transaction Documents or any matters, and the Company acknowledges that
the Investors are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations
or the transactions contemplated by the Transaction Documents. The decision of each Investor to purchase Purchase Shares pursuant
to the Transaction Documents has been made by such Investor independently of any other Investor. Each Investor acknowledges that
no other Investor has acted as agent for such Investor in connection with such Investor making its investment hereunder and that
no other Investor will be acting as agent of such Investor in connection with monitoring such Investor’s investment in the
Purchase Shares or enforcing its rights under the Transaction Documents. The Company and each Investor confirms that each Investor
has independently participated with the Company in the negotiation of the transaction contemplated hereby with the advice of its
own counsel and advisors. Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation,
the rights arising out of this Agreement or out of any other Transaction Documents, and it shall not be necessary for any other
Investor to be joined as an additional party in any proceeding for such purpose. The use of a single agreement to effectuate the
purchase and sale of the Purchase Shares contemplated hereby was solely in the control of the Company, not the action or decision
of any Investor, and was done solely for the convenience of the Company and not because it was required or requested to do so by
any Investor. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction
Document is between the Company and an Investor, solely, and not between the Company and the Investors collectively and not between
and among the Investors.


 






    -29-


     


    

 


(q)           Counsel
to Lead Investor. It is expressly understood and agreed by the Company and each of the Investors that Dorsey & Whitney
LLP has acted as counsel and has rendered legal advice only to the Lead Investor, and not to the Company, any other Investor or
any other Person in connection with the transactions contemplated by the Transaction Documents, and that each of the Company and
each Investor other than the Lead Investor has relied for such matters on the advice of its own respective legal counsel.


 


(r)            Expenses.
The Company has agreed to pay the Lead Investor the following: (i) $50,000 upon the signing of the term sheet relating to
this Agreement, and (ii) $50,000 upon the signing of this Agreement, as the full and complete expense reimbursement of the
Lead Investor’s expenses in connection with the transaction contemplated hereby, including any due diligence expenses and
legal fees.


 


* * * * *


 






    -30-


     


    

 


IN
WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the date first written
above.


 


	 	THE COMPANY:
	 	 
	 	ONCONOVA THERAPEUTICS, INC.
	 	 
	 	By:   	                      
	 	Name:
	 	Title:
	 	 
	 	INVESTORS:
	 	 
	 	[NAME]
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	[NAME]
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	[NAME]
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	[NAME]
	 	 
	 	By:	 
	 	Name:
	 	Title:


 






    -31-


     


    

 


SCHEDULES


 


	Schedule I 	Investors



 


EXHIBITS


 


	Exhibit A	Form of Officer’s Certificate
	Exhibit B	Form of Secretary’s Certificate
	Exhibit C	Information About Lincoln Park Furnished to the Company



 









    -32-


     


    

 


SCHEDULE I 


 


Investors


 


	Name and Address of Investor	Purchase Shares	Purchase Amount	State of Residence	Copies of Notices to:
	
         

         
	[       ]	$	
         

         

         

         

         
	 
	
         

         

         

         
	[         ]	$	 	 
	
         

         

         

         
	[         ]	$	 	 
	
         

         

         

         
	[         ]	$	 	 



 






    -33-